OptiBiotix Health delighted with progress

OptiBiotix Health continues to make progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies.

Highlights
• The appointment of Jim Laird as Commercial Director to the Board to increase commercial capacity and capability
• The completion of preclinical studies and ethics approval received to enable human clinical studies to begin for the Company’s cholesterol lowering product
• Expansion of the OptiBiotic® platform to a wider range of microbial species broadening the number of product and partner opportunities
• The filing of four new patents
• Creating a joint venture with Nizo Food Research to develop, manufacture and distribute weight management yoghurts to global markets
• Announcement of an option agreement with a multinational consumer goods company for the cholesterol lowering product
· Strategic alliance with Venture Life
· Agreement with Spanish National Research Council

Stephen O’Hara, CEO of OptiBiotix Health plc said: “I am delighted with the progress OptiBiotix has made since joining AIM in August 2014. In a short space of time we have moved one of our development programmes into clinical studies, progressed our sugar programme designed to create low calorie, sweet oligosaccharides to reduce chronic lifestyle disease such as heart disease, obesity and diabetes, built on our IP portfolio, and reached agreements with a number of commercial partners. During the period, we strengthened the Board with the appointment of Jim Laird, who has brought industry specific commercial and corporate expertise to the Company. I would like to thank our investors for their support since we joined AIM, and look forward to an exciting and rewarding rest of 2015.”

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.